“…administration [6], enabling reduction of CERA dose [7,8], improving iron use efficiency [7,9,10], and increasing erythropoiesis [6]. The guidelines on the management of renal anemia, published by the Japanese Society for Dialysis Therapy (JSDT) as the 2015 edition, suggest that CERA Q2W may be more effective than Q4W [11].…”